Haematologica
HOME HELP FEEDBACK ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Published online 26 March 2008
(Haematologica 2008, 10.3324/haematol.12265)
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Palandri, F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palandri, F.

Brief Reports

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome

Francesca Palandri1, Ilaria Iacobucci1, Fausto Castagnetti1, Nicoletta Testoni1, Angela Poerio1, Marilina Amabile1, Massimo Breccia2, Tamara Intermesoli3, Francesco Iuliano4, Giovanna Rege-Cambrin5, Mario Tiribelli6, Maurizio Miglino7, Fabrizio Pane8, Giuseppe Saglio5, Giovanni Martinelli1, Gianantonio Rosti1, Michele Baccarani2 on behalf of the GIMEMA Working Party on CML

1 Department of Hematology/Oncology "L. and A. Seràgnoli" S. Orsola Malpighi Hospital, University of Bologna, Bologna
2 Department of Cellular Biotechnology and Hematology, University "La Sapienza", Rome
3 Hematology Section, Bergamo
4 Division of Hematology, Catanzaro
5 Department of Clinical and Biological Science, University of Turin at Orbassano, Turin
6 Division of Hematology, University of Udine, Udine
7 Division of Hematology, University of Genova, Genova
8 CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy

Correspondence: Francesca Palandri, Department of Hematology and Oncology "L. and A. Seràgnoli", St. Orsola-Malpighi University Hospital, via Massarenti 9, 40138 Bologna, Italy. E-mail: francesca.palandri{at}libero.it

ABSTRACT

In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-{alpha} in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-{alpha}. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-{alpha} remains uncertain, due to low patient compliance.

Key words: chronic myeloid leukemia, imatinib, long-term results, interferon-alpha.






HOME HELP FEEDBACK ARCHIVE SUBSCRIPTIONS
Copyright © 2008 by the Ferrata Storti Foundation.